Foundation Resource Management Inc. Purchases 323,118 Shares of Pfizer Inc. (NYSE:PFE)

Foundation Resource Management Inc. raised its stake in Pfizer Inc. (NYSE:PFE) by 56.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 892,125 shares of the biopharmaceutical company’s stock after acquiring an additional 323,118 shares during the quarter. Pfizer comprises 3.6% of Foundation Resource Management Inc.’s holdings, making the stock its 11th largest position. Foundation Resource Management Inc.’s holdings in Pfizer were worth $22,606,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of PFE. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC increased its stake in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the 4th quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the 4th quarter valued at $30,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

PFE stock opened at $23.36 on Monday. The firm has a market cap of $132.81 billion, a PE ratio of 16.57, a P/E/G ratio of 0.64 and a beta of 0.57. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average of $22.95 and a 200-day moving average of $25.00. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the company earned $0.82 earnings per share. Pfizer’s revenue was down 7.8% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.36%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s payout ratio is currently 124.64%.

Wall Street Analyst Weigh In

PFE has been the topic of several recent research reports. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective on the stock. Finally, Citigroup reissued a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.